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OBJECTIVES The aim of this study was to investigate the potential role of brain natriuretic peptide (BNP)
levels in the assessment of functional status and right heart performance in primary
pulmonary hypertension (PPH).
BACKGROUND Primary pulmonary hypertension is a progressive disease leading to right heart failure and
death. Right heart catheterization and maximal or submaximal exercise tests are employed to
assess the course of the disease and the effect of therapeutic interventions. Additional
noninvasive and reproducible parameters would be helpful to assess the status of patients with
PPH. The natriuretic peptide system is up-regulated in PPH patients. Brain natriuretic
peptide (BNP) is produced from the cardiac ventricles and elevated in PPH. The aim of our
study was to evaluate the clinical significance of BNP in PPH patients.
METHODS Correlation analysis was performed for plasma BNP levels of 28 PPH patients and World
Health Organization (WHO) functional class (WHO-class), distance walked in 6 min, peak
oxygen uptake (peak VO2), and oxygen pulse during spiroergometry and various hemody-
namic parameters, including pulmonary vascular resistance (PVR), pulmonary artery pressure
(PAP), right atrial pressure (RAP), and cardiac index.
RESULTS The BNP levels were inversely correlated with the 6-min walk (r  0.70; p  0.001) and
peak VO2 (r  0.61; p  0.01), and positive correlation was observed with WHO-class (r
 0.79; p 0.001). Moreover, BNP levels were also correlated to PVR (r 0.61; p 0.01),
PAP (r  0.48; p  0.05), and RAP (r  0.78; p  0.01), and were inversely related to
cardiac index (r  0.48; p  0.05).
CONCLUSIONS Our data suggest that plasma BNP levels are closely related to the functional impairment of
PPH patients and parallel the extent of pulmonary hemodynamic changes and right heart
failure. Serial measurements of plasma BNP concentrations may help improve the manage-
ment of PPH patients. (J Am Coll Cardiol 2004;43:764–70) © 2004 by the American
College of Cardiology FoundationH
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hrimary pulmonary hypertension (PPH) is a progressive
isease leading to reduced functional status and a median
urvival of 2.8 years (1). According to our present
nderstanding, vascular remodeling, vasoconstriction,
nd thrombosis in situ play a role in the development of
PH (2). Increased pulmonary artery pressures (PAPs)
nd elevated pulmonary vascular resistance (PVR) cause
ight heart failure with low cardiac output (CO) and
levated right atrial pressures (RAPs) (3). Progressive
ight heart failure results in an impaired patient’s func-
ional capacity (4 –7). The clinical course of PPH is very
ariable; therefore, reliable parameters are needed to
haracterize the severity of the disease and to detect
isease progression sensitively. For that reason, repetitive
ight heart catheterization and cardiopulmonary exercise
esting, with submaximal (e.g., 6-min walk [6 MW]) or
aximal (spiroergometry) tests, are employed for evalu-
tion and follow-up of PPH patients (5). In addition,
hanges in exercise capacity have repeatedly been used to
ssess the effectiveness of different treatments (8 –11).
From the *Division of Pulmonary Diseases, Department of Internal Medicine I,
nd †Department of Clinical Chemistry, Ludwig Maximilians University, Klinikum
rosshadern, Munich, Germany. Paul A. Grayburn, MD, acted as the Guest Editor.
Manuscript received June 27, 2003; revised manuscript received September 4, 2003,tccepted September 11, 2003.owever, simple noninvasive and examiner independent
arameters could contribute significantly to the manage-
ent of PPH patients. Natriuretic peptides are potential
andidates in this respect. In left heart failure, high brain
atriuretic peptide (BNP) and atrial natriuretic peptide
ANP) levels are associated with impaired exercise capac-
ty (12) and a poor prognosis (13–17). In right heart
ailure resulting from PPH, limited data are available
howing an involvement of the natriuretic peptide system
18 –20). In particular, there are no data comparing serum
eptide levels with the functional status of PPH patients.
hus, BNP is predominately secreted by the cardiac
entricles (21) and therefore is of special interest in this
ontext.
The aim of our study was to establish BNP as a simple
xaminer-independent parameter for clinical assessment
f disease severity in patients with PPH. For that purpose
e performed correlation analysis for BNP levels and the
orld Health Organization functional class (WHO-
lass), the distance walked during the 6 MW, peak
xygen uptake (peak VO2), and oxygen pulse (O2-pulse)
uring spiroergometry as well as invasively measured
emodynamic parameters, during right heart catheteriza-
ion in 28 patients with PPH.
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wenty-eight patients (10 male, 18 female; mean age 46.9
ears) with PPH were included in the study. Underlying
auses for pulmonary hypertension were excluded according
o the criteria established during the WHO conference at
vian, France, 1998 (5). Exclusion criteria were non-PPH,
mpaired renal function (serum creatinine 1.3 mg/dl
nd/or impaired creatinine clearance) or any other signifi-
ant comorbidity. Vasodilative treatment at the time of
nrollment included calcium channel blockers (n  7),
loprost-aerosol (Ilomedin, Schering, Berlin, Germany) (n
16) and Beraprost sodium (Dorner, Yamanouchi-
harma, Tokyo, Japan) (n  2), respectively. The study
rotocol was approved by the institutional review commit-
ee. The BNP data were blinded until after the exercise, and
oth hemodynamic data and functional class were recorded.
ritten informed consent was obtained from every patient.
ll procedures adhered to the institutional guidelines.
ight heart catheterization. In 27 patients a Swan-Ganz
atheter (Criti-Cath, Becton Dickinson, Temse, Belgium)
nd an arterial catheter (Cordis, Johnson & Johnson,
iami, Florida) were inserted into the right femoral vein
nd artery, respectively. Hemodynamic measurements were
erformed in recumbent position. Continuous hemody-
amic monitoring included heart rate (HR), systemic and
ulmonary (PAP) artery blood pressures and transcutaneous
xygen saturation. Oxygen saturation was measured in
rterial and mixed venous blood samples (Hemoximeter,
adiometer, Copenhagen, Denmark). Additionally, blood
as analysis was performed in arterial blood samples (ABL
20, Radiometer, Copenhagen, Denmark). Additional pa-
ameters were pressures in wedge position and right atrium.
ardiac output was obtained, using triplicate measurements
ith the thermodilution method (cardiac output computer,
dwards Laboratories, Santa Ana, California). Cardiac
ndex, PVR, and systemic vascular resistance were calculated
sing standard formulas.
he 6-min walk test. The 6-min walk test was performed
n 26 patients using a standardized protocol in accordance to
he American Thoracic Society statement 2002 (22). Pa-
Abbreviations and Acronyms
ANP  atrial natriuretic peptide
BNP  brain natriuretic peptide
CO  cardiac output
PAP  pulmonary artery pressure
peak VO2  peak oxygen uptake
PPH  primary pulmonary hypertension
PVR  pulmonary vascular resistance
RAP  right atrial pressure
SvO2  mixed venous oxygen saturation
WHO-class  World Health Organization functional
class
6 MW  6-min-walk distanceients walked along an enclosed-level corridor; length to first Iurnaround point was 40 m. Technicians did not escort but
ncouraged patients using standard phrases such as “You are
oing well,” “Keep up the good work,” and were instructed
ot to use other encouragement. All patients were told to
se their own pace, but to cover as much ground as possible
n 6 min.
he WHO functional class assessment. The functional
lass of each patient was determined using a standardized
rotocol according to the classification of Evian 1998 (5),
ncluding questions concerning the patient’s daily life.
piroergometry. Spiroergometry was performed by 20 pa-
ients using a standardized protocol (23). All patients
erformed a progressively increasing working rate (10
·min1) to a maximum tolerated level on a electromag-
etically braked cycle ergometer. Blood gases were analyzed
uring the pre-exercise rest, exercise, and postexercise rest.
eart rate and pulse oximetry were monitored continuously,
nd noninvasive blood pressure was taken every 3 min. The
aximum work rate was recorded. Oxygen uptake (VO2),
inute ventilation, and CO2-output were calculated breath
y breath, interpolated, and averaged over 10-s periods.
eak oxygen uptake (peak VO2) and oxygen pulse (O2-
ulse) were calculated as described by Wasserman et al.
23).
ung function test. The complete set of pulmonary func-
ion tests included blood gas analysis in arterialized capillary
lood from the ear lobe, spirometry, body plethysmography,
nd single-breath diffusing capacity.
lood sampling and assay. In all patients (n  28) blood
amples were drawn and analyzed for routine laboratory
arameters (including renal function) and BNP. Blood
amples were drawn from the antecubital vein after at least
0 min of supine rest. The BNP samples were kept at 4°C
ntil centrifugation within 1 h; the plasma obtained was
ept at 20°C until analysis. Plasma BNP concentrations
ere quantified as described before (15) using a sandwich
adioimmunoassay (Shionoria BNP, CIS, Gif-sur-Yvette,
rance). The kit uses two different monoclonal antibodies;
he first antibody recognizes the C-terminal region of the
NP molecule and is coated onto beads as the solid phase.
he second antibody recognizes the intramolecular ring
tructure of BNP and is radiolabeled with iodine-125 as a
racer. Incubation is performed overnight. During a seven-
onth period and 31 analytical series, a coefficient of
ariation of 7.7% was found for a low concentration quality-
ontrol sample (mean 5.55 pmol/ml), and of 4.0% for a high
oncentration sample (mean 85.83 pmol/ml). The crossre-
ctivity of the assay toward ANP is specified as 1 
05%.
tatistical analysis. Data are shown as mean  SEM. The
tatistical software used was SPSS 11.0 for Windows. The
earson correlation coefficient was calculated for BNP and
or all other parameters, and was tested for two-sided
ignificance. Comparison between groups was tested for
ignificance using the nonparametric Mann-Whitney test.
n general, p values 0.05 were considered statistically
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Brain Natriuretic Peptide in PPH March 3, 2004:764–70ignificant. Correlations between hemodynamic and func-
ional parameters and BNP were only performed in those
atients who underwent the respective tests.
ESULTS
emodynamic parameters at rest. All patients had signif-
cant precapillary pulmonary hypertension (mean PAP 52.9
3.1 mm Hg); wedge pressure 7.8  0.6 mm Hg; PVR
,058.6 118.5 dyne·cm5·s1, and impaired cardiac index
2.1 0.1 l/min·m2). The RAP was 7.6 1.3 mm Hg. The
HO-class was distributed as follows: I (n  1), II (n 
9), III (n  6), and IV (n  2) (Table 1).
lasma BNP levels in PPH patients. Plasma BNP levels
ere significantly elevated in PPH patients (range, 1.16 to
67.33 pmol/ml; mean, 50.37 11.21 pmol/ml). The BNP
oncentrations showed significant correlations with the
ean PAP, PVR, and RAP obtained during right heart
atheterization. Cardiac index was inversely related to
lasma BNP levels (Table 1, Figs. 1 and 2). Correlation
etween plasma BNP levels and WHO-class was strong.
he 6 MW ranged from 180 to 600 m and was inversely
orrelated to plasma BNP levels. Peak VO2 ranged from 5.2
o 18.8 ml/kg·min1 and was also inversely related to
lasma BNP levels. Oxygen pulse also correlated inversely (r
Table 1. Patient Characteristics Including Hem
Levels, and Spirometry
Characteristics
Age (yrs) 46.9  3.2
Gender (M/F) 10/18
Specific treatment (n)
CCB 7
Iloprost-aerosol 16
Beraprost 2
None 3
Resting Hemodynamics All
PVR (dyne·cm5·s1) 1,058.6  11
Mean PAP (mm Hg) 52.9  3.
RAP (mm Hg) 7.6  1.
PCWP (mm Hg) 7.8  0.
CI (l/min·m2) 2.1  0.
Exercise performance
6 MW (m) 442.3  25
Peak VO2 (ml/kg·min
1) 12.5  0.
Oxygen pulse (ml·beat1) 7.3  0.
BNP
BNP levels (pmol/ml) 50.37  11
Spirometry
FEV1 (% predicted) 89.5  3.
VC (% predicted) 90.4  3.
DLCO (% predicted) 69.1  4.
PO2 (mm Hg) 60.3  2.
Comparison WHO II vs. WHO III: *p  0.05; †p  0.01
BNP  brain natriuretic peptide; CCB  calcium chan
FEV1  forced expiratory volume in 1 s; mean PAP  mean
pressure; peak VO2 peak oxygen uptake; PO2 arterial part
right atrial pressure; 6 MW  6-minute walk; VC  vital c0.49; p  0.05) with BNP levels. omparison between WHO functional classes. The
umber of patients with WHO functional class I (n  1)
nd class IV (n  2) was too small for further analysis.
omparison of WHO functional class II and class III
howed significant differences in BNP levels (p  0.001), 6
W (p  0.001), and peak VO2 (p  0.01). In contrast,
AP (p  0.05) was the only hemodynamic variable that
ignificantly differed between these two groups (Table 1,
ig. 3).
orrelation analysis of exercise and hemodynamic param-
ters. A strong inverse correlation existed between 6 MW
est and WHO functional class. Peak VO2 (r  0.73; p 
.001) and oxygen pulse (r 0.57; p 0.05) were positively
orrelated with the 6 MW. Even with high 6 MW test
esults between 400 and 500 m, we observed a positive
orrelation with peak VO2 (data not shown). With regard to
emodynamic parameters, the 6 MW correlated inversely
ith PVR (r0.48; p 0.05) and positively with cardiac
ndex (r  0.41; p  0.05). In addition, the 6 MW distance
howed an inverse correlation with the RAP (r  0.68; p
0.001) (Table 1, Fig. 3).
Peak VO2 during spiroergometry was inversely correlated
ith the functional class (r  0.73; p  0.001). The RAP
as significantly inversely correlated with peak VO2 (r 
namic Parameters, Exercise Tests, BNP
WHO II WHO III
924.3  102.7 1,224.5  102.7
50.4  3.3 59.6  3.0
4.6  0.6 13.8  1.4*
7.9  0.6 8  0.8
2.2  0.1 2.1  0.2
494.4  12.9 303.3  14.4‡
13.3  0.6 8.2  0.6†
7.3  0.4 5.7  0.4
23.03  5.06 99.36  7.8‡
92.6  3.5 81.7  2.6
93.9  3.2 83.0  2.3
66.1  4.8 72.8  2.7
59.7  2.4 58.3  2.4
0.001.
lockers; CI  cardiac index; DLCO  diffusing capacity;
onary artery pressure; PCWP  pulmonary capillary wedge
gen pressure; PVR pulmonary vascular resistance; RAP
y; WHO  World Health Organization functional class.ody
8.5
1
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apacit0.61; p  0.01). In addition, oxygen pulse showed a
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March 3, 2004:764–70 Brain Natriuretic Peptide in PPHignificant correlation with cardiac index (r  0.63; p 
.001) and an inverse correlation with PVR (r  0.60; p
0.05) (Table 1, Fig. 3).
omparison of treatment and lung function groups.
omparing different treatments with regard to BNP levels
r any other parameter we observed no statistically signifi-
ant differences or correlations between these groups (data
ot shown). Lung function test showed no correlation with
NP levels in any parameter, including spirometry and the
iffusion capacity (data not shown).
ISCUSSION
n this study we tried to establish plasma BNP as a
imple, noninvasive, and observer-independent parame-
er for assessing disease severity in patients with PPH.
e found robust correlations between BNP levels and
HO-class, the distance walked during the 6 MW test,
nd peak VO2 during spiroergometry. Additionally, we
ould demonstrate significant correlations between BNP
igure 1. (A to D) Correlation of resting hemodynamic parameters with br
A) Pulmonary vascular resistance (PVR) vs. BNP; r  0.61; p  0.001; (B
trial pressure (RAP) vs. BNP; r  0.78; p  0.001; (D) cardiac index (Cevels and hemodynamic parameters obtained during light heart catheterization. Based on our results we
onclude that plasma BNP concentration is an excellent
arker for assessing the functional impairment in PPH
atients due to right heart failure.
Plasma BNP levels have been shown to be related to
emodynamic parameters and are suggested to be of prog-
ostic value in patients with left or right heart failure. The
ajority of data from different investigators show that
lasma BNP levels are linked to hemodynamic indices of
eft ventricular function (14,24–26). Moreover, in chronic
eft heart failure and myocardial infarction, elevated plasma
NP levels have been associated with a poor prognosis
15,16). Only few reports deal with BNP levels in the
ontext of right ventricular dysfunction complicating pul-
onary artery hypertension of different etiologies (18,24).
oreover, there are no data relating BNP to the functional
apacity of patients with pulmonary hypertension.
Our results are in line with the hypothesis that the
atriuretic peptides are part of a physiologic counterregu-
atriuretic peptide (BNP) levels in primary pulmonary hypertension (PPH).
n pulmonary artery pressure (PAP) vs. BNP; r  0.49; p  0.01; (C) right
. BNP; r  0.48; p  0.05.ain n
) meaatory system in PPH patients with progressive right
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Brain Natriuretic Peptide in PPH March 3, 2004:764–70eart failure. In this context, activation of the natriuretic
eptide system will ameliorate pulmonary hypertension
wing to the direct vasodilatory properties of ANP and
NP (27) and indirectly by fluid loss. Both, ANP and are
eptide-hormones and act via ANP receptors (ANP-A,
NP-B, ANP-C). The ANP-A and ANP-B receptors
ctivate particulate guanylate cyclase and thus induce
ormation of cyclic guanosine monophosphate (cyclic
MP). The cyclic GMP serves as a second messenger
nd results in vasodilation, inhibition of the renin angio-
ension aldosterone system, and inhibition of sympathetic
ctivation (28). However, in left heart failure this linkage
s more complex in advanced disease. It has been de-
cribed that BNP levels are elevated to a higher degree
han cyclic GMP levels in severe congestive heart failure
13). Although this cannot be directly transferred to right
eart failure in pulmonary hypertension, there seems to
e a threshold of BNP above which cyclic GMP no
igure 3. (A, B) Correlation of World Health Organization (WHO)
unctional class with peak oxygen uptake (peak VO2) and 6-min walk (6
W) in primary pulmonary hypertension. (A) Correlation of WHO
unctional class with peak VO2; r  0.73; p  0.001; (B) correlation of
HO functional class with 6 MW; r  0.86; p  0.001.onger increases despite rising BNP production. Thisigure 2. (A to C) Correlation of exercise parameters with brain natriuretic
eptide (BNP) levels in primary pulmonary hypertension. (A) BNP vs.
-min walk; r  0.7; p  0.001; (B) BNP vs. peak oxygen uptake (peak
O2); r  0.61; p  0.01; (C) BNP vs. World Health Organization
WHO) functional class, r  0.79; p  0.001. WHO class II vs. class III;
 0.001.
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March 3, 2004:764–70 Brain Natriuretic Peptide in PPHould explain why increasing BNP levels are associated
ith disease progression and a bad prognosis. In the
ontext of PPH, ANP (19) plays a role in progressive
ight heart failure as it is highly activated in these
atients. Moreover, its secretion is decreased by applica-
ion of the pulmonary vasodilator iloprost (29) underlin-
ng sensitive regulation of the natriuretic peptides.
Predominant vasoconstrictors (30 –32) and vascular
emodeling lead to increased pulmonary pressures in
PH (2). Moreover, PAP and PVR increase further
uring exercise, owing to impaired pulmonary vasodila-
ion and recruitment (33). As a result, submaximal and
aximal exercise capacity (4) are decreased in PPH. For
hese reasons the 6 MW test and spiroergometry have
een of great value in identifying therapeutic effects of
ifferent vasodilators and in assessing a patient’s func-
ional status (7,8,11,34,35). In this context, peak VO2 has
een used as an excellent marker of exercise capacity in a
ariety of cardiopulmonary diseases as it integrates max-
mal CO, the potential of the exercising muscle to extract
xygen and the patient’s ventilatory capacity (6). Peak
O2 has repeatedly been shown to be decreased in PPH
6,23,36). Introduction of oxygen pulse allows correction
f oxygen uptake for the heart rate and is a suitable
arameter to describe exercise limitations caused by
iseases of the pulmonary circulation (23). Consequently,
ur data describe a close linkage between hemodynamics
nd maximal exercise impairment. In particular, RAP, a
arker of right heart failure, showed significant correla-
ion to peak VO2. In addition, oxygen pulse correlated
ignificantly with cardiac index and inversely with PVR.
In contrast to spiroergometry, the 6 MW test can be
erformed in advanced disease stage as it is a submaximal
xercise test. We found the distance during the 6 MW to be
ignificantly correlated to cardiac index and inversely corre-
ated to PVR and RAP. This finding confirms previous data
rom Miyamoto et al. (4).
To the best of our knowledge, there are no data
howing correlations between the natriuretic peptides
nd impaired functional status resulting from right heart
ailure in PPH. Our results demonstrated robust corre-
ations between plasma BNP levels and clinical status as
ell as functional parameters derived from maximal and
ubmaximal exercise testing. Additionally, only BNP
evels, 6 MW, and peak VO2 showed a statistically
ignificant difference between functional WHO class II
nd class III. In contrast, hemodynamics measured dur-
ng right heart catheter were not significantly different in
hese groups, except for the RAP.
Finally, long-term observational studies are necessary to
valuate BNP as a marker of disease progression and its role
n the assessment of treatment efficiency in PPH and other
orms of pulmonary hypertension as this information cannot
e drawn from our study. Thus far, our data suggest that
NP is a simple and clinically helpful parameter in the
valuation of PPH patients. 1eprint requests and correspondence: Dr. Hanno H. Leuchte,
ivision of Pulmonary Diseases, Department of Internal Medicine
, Ludwig Maximilians University, Klinikum Grosshadern, Mu-
ich Marchioninistr. 15, 81377 Munich, Germany. E-mail:
leuchte@helios.med.uni-muenchen.de.
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